Andrew Pollack writes for The New York Times: “About 10 percent of American women suffer from a lack of desire that causes distress, according to a survey conducted by an academic researcher but financed by Boehringer Ingelheim, the original developer of flibanserin. The drug, taken daily, would be for premenopausal women whose loss of desire was not from known causes like disease or the side effect of a drug.
Dr. Goldstein said it was gender bias to categorize male sexual dysfunctionas a simple physical problem and women’s as complex, psychological and unamenable to drugs.”